AnaptysBio
ANAB
45.65
-2.24
-4.68%
AnaptysBio
US · ANAB
#3010 by market cap
Listed 2017
45.65
-2.24
-4.68%
Live - 5344 symbols - heartbeat 62s ago
· 2026-10-08 08:13
Pre-market
45.63
-0.04%
After-hours
45.65
0.00%
- Market cap
- 1.36B
- P/E (TTM)i
- 8.15
- P/Bi
- 128.95
- EPSi
- 5.60
- Div yieldi
- 0.00%
- 52W posi
- 49%
Reader sentiment
Are you bullish or bearish on ANAB?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
80.00 +75.2%
Price target rangecurrent 45.65
Low60.00
Avg80.00
High95.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-09-30 | J.P. Morgan | -- | BUY | 60.00 |
| 2026-09-23 | Leerink Partners | -- | BUY | 81.00 |
| 2026-09-22 | UBS | -- | BUY | 76.00 |
| 2026-09-22 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-09-22 | Barclays | -- | BUY | 75.00 |
| 2026-09-18 | Leerink Partners | -- | BUY | -- |
| 2026-09-18 | Barclays | -- | BUY | 75.00 |
| 2026-08-25 | TD Cowen | -- | BUY | -- |
| 2026-08-24 | TD Cowen | -- | BUY | 70.00 |
| 2026-08-24 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-08-12 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-07-31 | Barclays | -- | BUY | 75.00 |
| 2026-07-23 | Barclays | -- | BUY | 75.00 |
| 2026-07-21 | Piper Sandler | -- | BUY | 93.00 |
| 2026-07-21 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-07-14 | Barclays | -- | BUY | 75.00 |
| 2026-07-13 | TD Cowen | -- | BUY | 75.00 |
| 2026-07-13 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-06-30 | UBS | -- | BUY | 76.00 |
| 2026-06-10 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-05-27 | Leerink Partners | -- | BUY | -- |
| 2026-05-22 | J.P. Morgan | -- | BUY | 70.00 |
| 2026-05-15 | Leerink Partners | -- | BUY | 90.00 |
| 2026-05-13 | TD Cowen | -- | BUY | 75.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 08:13:02 · For reference only, not investment advice and not tailored to your situation.